High Noon Recalls Vodka Seltzer Drinks Mislabeled as Celsius Energy Drinks
The Modesto, California-based company said in a bulletin, released Wednesday by the FDA, that some lots of its High Noon Beach Variety packs were 'mislabeled as Celsius Astro Vibe Energy Drink, Sparkling Blue Razz Edition with a silver top' but were 'filled with High Noon vodka seltzer alcohol' instead.
'Consumption of the liquid in these cans will result in unintentional alcohol ingestion,' said the recall notice from High Noon, which is owned by the winemaking giant E & J Gallo Winery.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Products with opioid-like effects sold at gas stations may be banned as illicit substances
The Food and Drug Administration (FDA) is recommending banning a compound found in unregulated tablets, gummies and drink mixes sold online and at gas stations and convenience stores, the Trump administration announced this week. The substance, known as 7-OH, will be scheduled as an illicit drug if the Drug Enforcement Administration − a branch of the US Justice Department responsible for classifying drugs as controlled substances − approves the sanction after a review. "Dark innovations in chemistry have exacerbated the addiction crisis in this country," US Department of Health and Human Services Deputy Secretary Jim O'Neil told reporters during a Tuesday, July 29, press conference in Washington DC. "Synthetic opioids like carfentanill and the substance we're here to take action on today: 7-Hydroxymitragynine." O'Neil said 7-hydroxymitragynine, 7-OH, is deliberately addictive and a powerful opioid agonist many times more potent than morphine. Calling it "a recipe for public health disaster," O'Neill, said 7-OH products are often sold without warnings or controls. "We've seen a disturbing rise in reports of overdoses, poisonings and emergency room visits linked to products containing 7-OH,' O'Neil said. "These substances are often sold online or in convenience stores with no quality control, no dosage control and no warnings." 'They've killed thousands and thousands' During the press conference, FDA commissioner Martin Makary spoke alongside US Health and Human Services Secretary Robert F. Kennedy, Jr., as they announced they planned to send warning letters to companies for illegally marketing products containing 7-OH in an effort to combat the country's opioid addiction problem. 'We have a history in public health of being asleep at the wheel,' Makary said. 'Public health is supposed to prevent disasters, not just clean them up after they've killed thousands and thousands of people.' Which states felt tsunami waves? See list of where it hit after Russia earthquake What is 7-OH? The compound 7-OH is a naturally occurring substance in the kratom plant (Mitragyna speciosa), according to the FDA, but only a minor component comprising less than 2% of the alkaloid content in natural kratom leaves. "However, 7-OH demonstrates substantially greater mu-opioid receptor potency than kratom's primary alkaloid constituent mitragynine, as well as other classical opioids such as morphine," the FDA wrote in its findings. Mu-opioid receptors, found in the brain and spinal cord, are primarily responsible for pain relief and other opioid effects like euphoria and respiratory depression, according to research published on the National Institutes of Health's National Library of Medicine. Contributing: Adrianna Rodriguez Natalie Neysa Alund is a senior reporter for USA TODAY. Reach her at nalund@ and follow her on X @nataliealund. (This story was updated to include video.) This article originally appeared on USA TODAY: What is 7-OH? Opioid-like product may get banned by FDA Solve the daily Crossword
Yahoo
2 hours ago
- Yahoo
Health officials issue warning after finding dead birds with dangerous virus: 'An early warning sign'
Health officials issue warning after finding dead birds with dangerous virus: 'An early warning sign' Three dead birds in California's Sacramento County have tested positive for West Nile virus. What's happening? The Sacramento Bee summarized an announcement from the Sacramento-Yolo Mosquito and Vector Control District, which said these were the first three birds to be identified with the virus in the county this year. However, a mosquito sample 3.5 weeks ago tested positive for the virus. "Finding the first positive birds is always significant because it serves as an early warning sign for West Nile virus activity," Gary Goodman, the district manager, said in a statement. "It confirms the virus is present in our region, helps us identify areas where infected mosquitoes may be found, and provides insight into where human cases could emerge later in the season." Why is West Nile virus important? Although West Nile virus has been in the United States since at least 1999, when it was discovered in New York, recent reports signal that it's showing up earlier in the season. Such is the case in Massachusetts, which recently discovered its first West Nile-carrying mosquitoes for the year. Many scientists attribute this shift to a warming planet, which enables disease-spreading mosquitoes to stay active for longer periods throughout the year. Plus, these bloodsuckers are beginning to expand their ranges and move into higher altitudes. For instance, Connecticut officials are warning residents that a type of mosquito that can carry chikungunya, Zika, and dengue is expected to spread farther and faster across the state in 2025. Symptoms of West Nile include fever, headache, body aches, vomiting, diarrhea, or rash, according to the Centers for Disease Control and Prevention. However, the virus sometimes turns deadly. In 2024, the CDC reported 164 deaths attributed to West Nile. The Bee reported that a man in the San Joaquin Valley, which borders Sacramento County, died partly because of the virus, making it the first West Nile-related death in the state this year. What's being done about West Nile? According to the Bee, area officials are spraying insecticide to limit the spread of West Nile, and the Sacramento-Yolo Mosquito and Vector Control District is amping up its efforts to monitor and trap mosquitoes. The district also directs citizens to its website, which has updates and mosquito bite prevention tips, including draining standing water that can attract mosquitoes and avoiding spending time outdoors at dawn and dusk. Meanwhile, communities across the globe are looking for ways to reduce their mosquito populations to protect residents from illnesses such as West Nile. For example, one Florida county is using X-rays to kill invasive mosquitoes. And one neighborhood in the Philippines is paying residents to bring in any mosquitoes they can capture, dead or alive. Do you worry about air pollution in your town? All the time Often Only sometimes Never Click your choice to see results and speak your mind. Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the the daily Crossword
Yahoo
5 hours ago
- Yahoo
New RADIOHEAD Study Validates Use of Guardant Reveal Tissue-Free Monitoring for Earlier Detection of Immunotherapy Response in Advanced Cancer
The first readout from Guardant's research collaboration with the Parker Institute for Cancer Immunotherapy (PICI) shows Guardant Reveal detected responses to immunotherapy across multiple tumor types and identified non-responders up to 5 months earlier than standard methods Study shows Guardant Reveal's promise for confirming effective therapies earlier and optimizing treatment faster in patients with advanced cancer PALO ALTO, Calif., July 29, 2025--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the first clinical readout from their collaboration in the RADIOHEAD study with the Parker Institute for Cancer Immunotherapy (PICI), a network of the largest concentration of immuno-oncology (IO) expertise in the world. The data, published today in Cancer Research Communications, a journal of the American Association for Cancer Research, found that Guardant Reveal successfully detected responses to immunotherapy across multiple solid tumor types in advanced stage cancer patients and identified non-responders more than three months—and in some cases nearly five months—before disease progression was visible by standard methods. Approximately 30% of patients with advanced-stage cancer receive immunotherapy treatment, with varying degree and duration of response. This study analyzed a large cohort of more than 500 patients with various advanced solid tumors, including lung, skin, head and neck, breast, GI, GU, and gynecologic cancers, receiving immunotherapy in a real-world setting to assess if blood-based monitoring could predict response accurately and faster than standard of care methods. The strong association found between long-term patient outcomes and changes in tumor fraction as measured with the tissue-free, methylation-based Guardant Reveal supports the use of blood-based monitoring to help predict treatment response and improve decision-making in cancer care. "Precise serial monitoring at the molecular level provides real value to oncologists and to patients using immunotherapy," said Craig Eagle, M.D., Chief Medical Officer at Guardant Health. "This study shows that Guardant Reveal has the potential to revolutionize how oncologists assess patient response, identifying earlier insights that can empower them to make informed decisions faster and improve patient outcome and quality of care." "Our RADIOHEAD study of Guardant Reveal in advanced stage cancers provides patients with a new caliber of precision monitoring in order to create better patient outcomes," said Tarak Mody, PhD, Chief Business Officer at PICI. "These findings exemplify PICI's commitment to forging mission-driven partnerships to bring cutting-edge technology into clinical practice, accelerate discoveries, and advance the development of curative immune therapies for patients." Key study findings include: Improved patient outcomes associated with any reduction in tumor fraction 75% lower risk of progression in patients with ≥80% decrease in tumor fraction Disease progression identified up to 5 months prior to standard of care methods The full manuscript in Cancer Research Communications is available here. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit and follow the company on LinkedIn, X (Twitter) and Facebook. About RADIOHEAD The RADIOHEAD (Resistance Drivers for Immuno-Oncology Patients Interrogated by Harmonized Molecular Datasets) program is a pan-tumor, prospective cohort study of 1,070 immunotherapy-naïve patients receiving standard-of-care immune checkpoint inhibitor regimens. Conducted across 49 U.S. community oncology clinics, the study includes over 3,700 longitudinal blood samples collected at pretreatment, early on-treatment, and immune-related adverse event timepoints, with a focus on major immuno-oncology indications such as non-small cell lung cancer (~1,400 samples) and malignant melanoma (~500 samples). Multi-omic profiling (including circulating tumor DNA analysis, whole-exome sequencing, transcriptomics, high-dimensional immune profiling, and serum proteomics) is paired with detailed clinical and demographic data to enable deep translational insights. This comprehensive dataset provides a unique opportunity to uncover mechanisms of response, resistance, and toxicity, and to apply machine learning approaches to explore immune and disease pathways. Guardant Health Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release. View source version on Contacts Investor Contact: Zarak Khurshidinvestors@ Media Contact: Meaghan Smithpress@
